TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20459404

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day, n=48)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard therapy (n=15)
Number of subjects: 63
Study: 18514166

Group type: EXPERIMENTAL
Intervention: Prodromal subjects and unmedicated first-episode schizophrenia patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients treated with risperidone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 54

Group type: COMPARATOR
Intervention: Prodromal subjects and schizophrenia patients
Number of subjects: 54
Study: 16160627

Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (3 mg/kg daily for 6 months)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11803237

Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg) in severity stratum 1 (MMSE >23)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg) in severity stratum 2 (MMSE <24)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo in severity stratum 1 (MMSE >23)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo in severity stratum 2 (MMSE <24)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg) in patients with very mild to mild cognitive impairment
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg) in patients with more severe dementia
Number of subjects: 52
Study: 10598610

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative atenolol
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intraoperative atenolol
Number of subjects: 63

Group type: COMPARATOR
Intervention: No atenolol
Number of subjects: 63
Study: 7863761

Group type: EXPERIMENTAL
Intervention: Horizontal laminar flow ventilation and conventional clothes (cotton shirts and trousers)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Horizontal laminar flow ventilation and occlusive garments (Klinidress)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional ventilation and occlusive garments
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Horizontal laminar flow ventilation with occlusive clothes during knee arthroplasty
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Horizontal laminar flow ventilation during hip arthroplasty
Number of subjects: 90
Study: 1722989

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-steroid treatment
Number of subjects: 50
Study: 6175494

Group type: EXPERIMENTAL
Intervention: Propafenon (3 x 150 mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Propranolol (3 x 20 mg daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propafenon plus Propranolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propafenon alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 15
Study: 29904203

Group type: EXPERIMENTAL
Intervention: Sprayed-dried colostrum-based (CR; n = 8)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Plasma-based colostrum replacement product (PR; n = 9)
Number of subjects: 17
Study: 26821116

Group type: EXPERIMENTAL
Intervention: Yogurt smoothies alone (YS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Smoothies with BB-12 added before yogurt fermentation (PRE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BB-12 capsule (CAP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Smoothies with BB-12 added after yogurt fermentation (POST)
Number of subjects: 30
Study: 24557111

Group type: EXPERIMENTAL
Intervention: Individualized PEEP (10 ± 2 cm·H2O)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Individualized PEEP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standardized PEEP (5 cm·H2O)
Number of subjects: 30
Study: 22763899

Group type: EXPERIMENTAL
Intervention: TAP block with levobupivacaine 0.375% 20 mL
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham block with 20 mL 0.9% saline (Control)
Number of subjects: 65
Study: 20388624

Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4% gelatin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: gelatin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 17894937

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 174

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 174
Study: 15921806

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Carvedilol (stayed on the same drug)
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Metoprolol (stayed on the same drug)
Number of subjects: 1321
Study: 12067005

Group type: EXPERIMENTAL
Intervention: 2% articaine with epinephrine 1:200,000
Number of subjects: 82

Group type: COMPARATOR
Intervention: 0.5% bupivacaine and 2% lidocaine with epinephrine 1:200,000
Number of subjects: 82
Study: 10653861

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 8862164

Group type: EXPERIMENTAL
Intervention: Enhanced HIV Prevention Counseling (4 sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV Prevention Counseling (2 sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV Education (2 sessions)
Number of subjects: 0
Study: 1538559

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Weight loss diet
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Low sodium/high potassium diet
Number of subjects: 593
Study: 6467282

Group type: EXPERIMENTAL
Intervention: Cefazolin 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 gm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefazolin 2 gm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cephalothin 2 gm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cephapirin 1 gm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefoxitin 1 gm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefamandole 0.5 gm
Number of subjects: 0
Study: 31779922

Group type: EXPERIMENTAL
Intervention: MRA treatment
Number of subjects: 1756

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1756
Study: 29702283

Group type: EXPERIMENTAL
Intervention: Sublingual Immunotherapy (SLIT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional anti-allergic medications (Control)
Number of subjects: 26
Study: 26992569

Group type: EXPERIMENTAL
Intervention: CBT+ITS (intensive text-message and e-mail support)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CBT+MTS (minimal text-message support)
Number of subjects: 60
Study: 25311734

Group type: EXPERIMENTAL
Intervention: Sunlight-derived ultraviolet radiation (UVR) exposure over 6 months
Number of subjects: 248
Study: 22991405

Group type: EXPERIMENTAL
Intervention: Chronic PDE5I (sildenafil® 20 mg tid for 12 weeks followed by 60 mg tid for 12 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic PDE5I (sildenafil®)
Number of subjects: 0
Study: 20415618

Group type: EXPERIMENTAL
Intervention: Telephonic nurse disease management program (DM) including educational materials, lifestyle and diet counseling, and home BP monitor
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Telephonic nurse disease management program (DM)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Home BP monitor alone
Number of subjects: 485
Study: 17321104

Group type: EXPERIMENTAL
Intervention: High social anxiety individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low social anxiety individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distraction coping
Number of subjects: 0
Study: 15930452

Group type: EXPERIMENTAL
Intervention: Olestra-containing diet with daily multivitamin (Centrum)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control diet (33% energy from fat)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Fat-reduced diet (25% of energy from fat)
Number of subjects: 37
Study: 12875315

Group type: EXPERIMENTAL
Intervention: Symptomatic cyclists
Number of subjects: 24

Group type: COMPARATOR
Intervention: Asymptomatic cyclists
Number of subjects: 24
Study: 10226125

Group type: EXPERIMENTAL
Intervention: Microlaparoscopic ovarian coagulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional laparoscopic ovarian coagulation
Number of subjects: 18
Study: 8967669

Group type: EXPERIMENTAL
Intervention: Accelerated alteplase therapy
Number of subjects: 41021

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 41021
Study: 1725890

Group type: EXPERIMENTAL
Intervention: Cromakalim 1 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cromakalim 2 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6091484

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g single dose)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cefazolin (seven doses)
Number of subjects: 104
Study: 30733268

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 56

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 56
Study: 29633339

Group type: EXPERIMENTAL
Intervention: Intraduodenal acetic acid infusion (50 mL)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Saline (50 mL)
Number of subjects: 210
Study: 26791556

Group type: EXPERIMENTAL
Intervention: Infancy iron supplementation (∼1 mg Fe/(kg · d) as oral iron proteinsuccynilate)
Number of subjects: 1276
Study: 24858737

Group type: EXPERIMENTAL
Intervention: Low-power fractional CO2 laser
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-fluence Q-switch 1,064 nm Nd:YAG laser
Number of subjects: 40
Study: 23217054

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Strength Training
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo Control (Seated Stretching Exercise)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Maximal Leg Strength
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Postural Stability
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Physical Function
Number of subjects: 429
Study: 20350920

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment (50 to 100 mcg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17545843

Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 on days 1 and 8, every 21 days for three cycles, followed by Docetaxel 35 mg/m2 on days 1, 8, and 15, every 28 days for three cycles (S0027)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Docetaxel 30 mg/m2 on days 1, 8, and 15, every 28 days, or 75 mg/m2 every 21 days (LUN 6)
Number of subjects: 228

Group type: COMPARATOR
Intervention: N/A (under-80 cohort from S0027 as control)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: N/A (80-and-older group)
Number of subjects: 228

Group type: COMPARATOR
Intervention: N/A (under-80 group)
Number of subjects: 228
Study: 17524571

Group type: COMPARATOR
Intervention: 50 Gy Whole-Breast Irradiation (WBI)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 7 x 5.2 Gy High-Dose-Rate Brachytherapy (HDR-BT)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 50 Gy Electron Irradiation (ELE)
Number of subjects: 258
Study: 15500893

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (22 microg)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 11526363

Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg once daily for 24 weeks
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 9290854

Group type: EXPERIMENTAL
Intervention: Bulimia nervosa with comorbid alcohol dependence
Number of subjects: 114

Group type: COMPARATOR
Intervention: Bulimia nervosa without alcohol dependence
Number of subjects: 114
Study: 8322247

Group type: EXPERIMENTAL
Intervention: 5 mg of terbutaline nebuliser solution
Number of subjects: 21
Study: 3575033

Group type: EXPERIMENTAL
Intervention: Whey-predominant formula (ratio of whey proteins to caseins of 60:40)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Casein-predominant formula (ratio of whey proteins to caseins of 18:82)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whey-predominant formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 0
Study: 31917054

Group type: EXPERIMENTAL
Intervention: Early-stage periarticular injection (injection just before arthrotomy)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Late-stage periarticular injection (placebo before arthrotomy, injection after implantation)
Number of subjects: 140
Study: 31160295

Group type: EXPERIMENTAL
Intervention: IV methotrexate (MTX)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral (PO) methotrexate (MTX)
Number of subjects: 44
Study: 28399112

Group type: EXPERIMENTAL
Intervention: Cetuximab plus Nordic FLOX (continuous or intermittent fluorouracil, folinic acid, and oxaliplatin)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Cetuximab monotherapy
Number of subjects: 566

Group type: COMPARATOR
Intervention: Nordic FLOX alone
Number of subjects: 566
Study: 26079800

Group type: EXPERIMENTAL
Intervention: Adductor canal catheter (3-day ropivacaine 0.2% infusion)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Femoral catheter (3-day ropivacaine 0.2% infusion)
Number of subjects: 80
Study: 23500537

Group type: EXPERIMENTAL
Intervention: Plant sterol margarine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Plant stanol margarine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 43
Study: 21198901

Group type: EXPERIMENTAL
Intervention: modSLA implants
Number of subjects: 22

Group type: COMPARATOR
Intervention: SLA implants
Number of subjects: 22
Study: 19216016

Group type: EXPERIMENTAL
Intervention: Pentoxifylline, 400 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pentoxifylline and Placebo
Number of subjects: 40
Study: 16769831

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 243
Study: 15111342

Group type: EXPERIMENTAL
Intervention: Infusional 5-FU 200 mg/m² daily continuous infusion for 18 weeks with epirubicin 60 mg/m² and cisplatin 60 mg/m² (infusional ECisF)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Conventional bolus doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² (AC)
Number of subjects: 426
Study: 11574128

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 241

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 241
Study: 9855373

Group type: EXPERIMENTAL
Intervention: Indirect calorimetry measurement
Number of subjects: 15

Group type: COMPARATOR
Intervention: No indirect calorimetry measurement
Number of subjects: 15
Study: 7864679

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bladder carcinoma patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Undifferentiated tumors (Broders' classification 1, 2, 3, and 4)
Number of subjects: 50
Study: 2592090

Group type: EXPERIMENTAL
Intervention: Admission to hospital for 24 hours
Number of subjects: 114

Group type: COMPARATOR
Intervention: Discharge from the accident department
Number of subjects: 114
Study: 31738014

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 301

Group type: COMPARATOR
Intervention: No TENS
Number of subjects: 301
Study: 31286731

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with grain‐moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 60
Study: 28254231

Group type: EXPERIMENTAL
Intervention: Cervical ripening balloon (CRB) group with double‐balloon catheter (COOK CRB), inflated with 30‐80 mL of normal saline for 12 hours
Number of subjects: 167

Group type: COMPARATOR
Intervention: Non-CRB group (vaginal and oral misoprostol alone)
Number of subjects: 167
Study: 26429398

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 646

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 646
Study: 22946635

Group type: EXPERIMENTAL
Intervention: Yogurt containing Lactobacillus rhamnosus GG (LGG) and fructooligosaccharide (FOS) Actilight(®) administered daily for 4 weeks
Number of subjects: 0
Study: 21658884

Group type: EXPERIMENTAL
Intervention: 2 mL of 1% lidocaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: 2 mL of 0.9% NaCl
Number of subjects: 120

Group type: COMPARATOR
Intervention: No infiltration
Number of subjects: 120
Study: 19366275

Group type: EXPERIMENTAL
Intervention: Ivabradine 10 mg twice daily for 7 days, followed by 15 mg twice daily if no visual symptoms reported
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 16686575

Group type: EXPERIMENTAL
Intervention: Stability Ball Training (SBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 20
Study: 15823773

Group type: EXPERIMENTAL
Intervention: Sibutramine mesylate hemihydrate (17.3 mg oral dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sibutramine hydrochloride monohydrate (15 mg oral dose)
Number of subjects: 16
Study: 11700399

Group type: EXPERIMENTAL
Intervention: rTFPI at 0.025 mg/kg/hr
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: rTFPI at 0.05 mg/kg/hr
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: rTFPI (both doses)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 9404177

Group type: EXPERIMENTAL
Intervention: Enflurane administered via a laryngeal mask airway (LMA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enflurane anaesthesia administered using a face mask
Number of subjects: 40
Study: 8008999

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study: 2961307

Group type: EXPERIMENTAL
Intervention: Continuous administration of 5'-DFUR (800 mg/m2/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intermittent administration of 5'-DFUR (1,400 mg/m2/day for 4 days followed by 3 days off)
Number of subjects: 21
Study: 29455237

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water-based lubricant
Number of subjects: 100
Study: 28804223

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ischemia-reperfusion (I/R) group
Number of subjects: 40
Study: 26469131

Group type: EXPERIMENTAL
Intervention: Teacher-led intervention (TL)
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: Researcher-led intervention (RL)
Number of subjects: 1707

Group type: COMPARATOR
Intervention: Control group (lessons as usual)
Number of subjects: 1707
Study: 22759198

Group type: EXPERIMENTAL
Intervention: Apixaban 0.5-2.5 mg as solution or 5-50 mg as tablets
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 20842166

Group type: EXPERIMENTAL
Intervention: [(57)Fe]-ferrous fumarate
Number of subjects: 3

Group type: COMPARATOR
Intervention: [(58)Fe]-ferrous sulfate
Number of subjects: 3
Study: 18332775

Group type: EXPERIMENTAL
Intervention: Flat chair intervention
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Curved chair intervention
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group (placebo intervention)
Number of subjects: 293
Study: 17154734

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 56
Study: 14719426

Group type: EXPERIMENTAL
Intervention: Adenosine 10 mg in 5 ml saline with prilocaine 1% 10 ml and lignocaine 2% 20 ml with adrenaline 1:200,000 (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5 ml saline (placebo control) with prilocaine 1% 10 ml and lignocaine 2% 20 ml with adrenaline 1:200,000 (Group 2)
Number of subjects: 50
Study: 10840426

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Transurethral prostatic resection
Number of subjects: 340

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 340
Study: 9386847

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8197031

Group type: EXPERIMENTAL
Intervention: Hydrocodone bitartrate 7.5 mg with acetaminophen 500 mg
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Codeine phosphate 30 mg with acetaminophen 300 mg
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 3147522

Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg twice daily for 1 week)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 1 week)
Number of subjects: 114
Study: 31346609

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) therapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ongoing injection drug use (IDU)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Reporting ongoing IDU
Number of subjects: 150
Study: 31329983

Group type: EXPERIMENTAL
Intervention: Vitamin E 30 IU/kg (VE30)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Salmonella Enteritidis (SE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiological saline solution (PS)
Number of subjects: 80
Study: 29137041

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 144

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 144
Study: 26169935

Group type: EXPERIMENTAL
Intervention: Leucine alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: EAAs with leucine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: EAAs
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (flavored water)
Number of subjects: 9